Shield Therapeutics plc (AIM:STX)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 94.56M |
| Revenue (ttm) | 36.93M |
| Net Income (ttm) | -13.12M |
| Shares Out | 1.07B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,316,901 |
| Average Volume | 2,220,688 |
| Open | 8.93 |
| Previous Close | 8.85 |
| Day's Range | 8.60 - 9.19 |
| 52-Week Range | 2.20 - 12.50 |
| Beta | 1.91 |
| RSI | 47.58 |
| Earnings Date | Jun 4, 2026 |
About Shield Therapeutics
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom. [Read more]
Financial Performance
In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.
Financial numbers in USD Financial StatementsNews
Shield Therapeutics Earnings Call Transcript: Q4 2025
Cash flow positive in Q4 2025, with $50M in annual revenue and 56% U.S. growth. ACCRUFeR leads the U.S. market, with international expansion and new pediatric indications underway. Profitability and further portfolio diversification targeted for 2026.
Shield Therapeutics Transcript: Trading Update
Q3 2025 saw strong revenue and prescription growth for Accrufer, with robust digital and sales force strategies driving market expansion. Cash flow positivity is expected by Q4 2025, and ex-U.S. growth continues with new launches and regulatory progress. Influencer marketing and targeted outreach are delivering measurable results.
Shield Therapeutics Transcript: Trading Update
ACCRUFeR saw record Q2 growth, doubling net revenues to $12.8 million and achieving 47,000 prescriptions, driven by expanded digital marketing and optimized sales force. Global partnerships and pediatric expansion support continued momentum, with cash flow positivity targeted by end-2025.
Shield Therapeutics Transcript: Trading Update
ACCRUFeR sales rebounded strongly in Q1 2025 after weather disruptions, with March delivering the second highest non-consignment sales ever. Strategic focus on digital marketing, sales force realignment, and reducing consignment business supports confidence in reaching cash flow positivity by year-end.
Shield Therapeutics Transcript: Trading Update
ACCRUFeR achieved strong 2024 growth, with revenues up 153% and a focus on higher-margin sales. Strategic realignment, expanded digital marketing, and global launches are expected to drive further growth and support the goal of cash flow positivity by end of 2025.
Shield Therapeutics Transcript: Trading Update
Q3 2024 saw strong ACCRUFeR prescription growth and stable pricing, with revenues reaching $7.2 million and a 20% increase in volume. Cost reductions, expanded financing, and a planned $10 million equity raise aim to achieve cash flow positivity by end-2025. Ongoing global expansion and robust U.S. market performance support a positive outlook.
Shield Therapeutics Earnings Call Transcript: H1 2024
H1 2024 saw ACCRUFeR revenues triple year-over-year, driven by U.S. growth and global partnerships. Break-even is targeted for H2 2025, with further price and prescription growth expected. Liquidity was bolstered by milestone monetization and financing initiatives.
Shield Therapeutics Transcript: Trading Update
Shield Therapeutics Transcript: Trading Update
Shield Therapeutics Earnings Call Transcript: H2 2022
Shield Therapeutics Earnings Call Transcript: H2 2021
Shield Therapeutics Transcript: Investor Update
OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX
NEW YORK, May 17, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics PLC (LSE: STXS; OT...